Clinical Trial

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI

Name: Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI — clinical trial record (NCT06633718)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a Phase 3, randomized, double-blind, multicenter, positive control study to assess the efficacy, safety, and pharmacokinetics of Meropenem and Pralurbactam compared with Ceftazidime-avibactam in combination with Metronidazole in the treatment of adult complicated intra-abdominal infections (cIAI).

Trial Details

NCT Number	NCT06633718
Lead Sponsor	Qilu Pharmaceutical Co., Ltd.
Conditions	Intra-abdominal Infections
Enrollment	786 participants
Start Date	2024-10-31
Primary Completion	2027-05-30 (estimated)
Study Completion	2027-05-30 (estimated)
Updated on ClinicalTrials.gov	2024-10-09